Smokers more likely to experience vision loss

News
Article

Research indicates smoking increases risk of AMD, cataracts and glaucoma

A no smoking sign hanging on a wall. ©stock.adobe.com – generated with Firefly AI

National No Smoking Day is on Wednesday 13 March in the UK. ©stock.adobe.com – generated with Firefly AI

The risks associated with smoking are not limited to increased risks of cancer and heart disease. Smoking also can be detrimental to vision. In fact, smokers are more likely to experience visual loss, according to a press release issued by Moorfields Eye Hospital, London, in anticipation of National No Smoking Day on Wednesday 13 March in the UK.

Consultant ophthalmologist Mr Luke Nicholson, who leads the medical retina services at Moorfields Eye Hospital, flags the increased associated risks with age-related macular degeneration (AMD).

Eye care providers at Moorfields state that more public awareness is needed regarding the risks associated with smoking and sight loss, because less is known about the effects of smoking on ocular health.

According to Mr Nicholson, “In my role, I have seen the negative impact that smoking has on patients. Quitting smoking brings clear benefits to our health but also protects our retina from developing some irreversible diseases and safeguards our vision.”

Research shows that smoking has been associated with increasing the risk of developing AMD, cataracts and glaucoma.

AMD is the most common cause of sight loss in the UK. If patients already have some form of AMD, research indicates that smoking may also be associated with progression to more advanced forms of the disease.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.